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Background: The membrane-proximal external region (MPER) of HIV-1 gp41 is particularly conserved and target for
the potent broadly neutralizing monoclonal antibodies (bnMAbs) 2F5, 4E10 and 10E8. Epitope focusing and
stabilization present promising strategies to enhance the quality of immune responses to specific epitopes.
Results: The aim of this work was to design and evaluate novel immunogens based on the gp41 MPER with the
potential to elicit cross-clade neutralizing antibodies. For that purpose, gp41 was truncated N-terminally in order to
dispose immunodominant, non-neutralizing sites and enhance the exposure of conserved regions. To stabilize a
trimeric conformation, heterologous GCN4 and HA2 zipper domains were fused based on an in silico “best-fit”
model to the protein’s amino terminus. Cell surface exposure of resulting proteins and their selective binding to
bnMAbs 2F5 and 4E10 could be shown by cytometric analyses. Incorporation into VLPs and preservation of
antigenic structures were verified by electron microscopy, and the oligomeric state was successfully stabilized by
zipper domains. These gp41 immunogens were evaluated for antigenicity in an immunization study in rabbits
primed with homologous DNA expression plasmids and boosted with virus-like particle (VLP) proteins. Low titers of
anti-MPER antibodies were measured by IgG ELISA, and low neutralizing activity could be detected against a clade
C and B viral isolate in sera.
Conclusions: Thus, although neutralizing titers were very moderate, induction of cross-clade neutralizing antibodies
seems possible following immunization with MPER-focusing immunogens. However, further refinement of MPER
presentation and immunogenicity is clearly needed to induce substantial neutralization responses to these
epitopes.
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The development of a preventive vaccine against human
immunodeficiency virus type 1 (HIV-1) has been pur-
sued by many research groups around the globe using a
variety of approaches [1]. Broadly neutralizing antibodies
(bnAbs) are thought to be a critical component of an ef-
fective immune response. Eliciting such antibodies by
vaccination has proven to be difficult due to the substan-
tial genetic variation of HIV-1 and its ability to evade
host immune defenses by different mechanisms [2].* Correspondence: ralf.wagner@klinik.uni-regensburg.de
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unless otherwise stated.Although bnAbs alone may not be able to fully control
HIV-1 replication once the infection has been estab-
lished, they can protect at low titers if they are present
in immunologically relevant sites, as has been shown
in several passive immunization experiments in non-
human primate studies [3].
Besides the surface protein gp120, the transmembrane
protein gp41 is target for bnAbs during infection [4],
rendering this protein a worthwhile target for vaccine
design. According to the currently accepted model for
HIV-1 fusion [5], following engagement of host cellular
receptors, the viral envelope trimer undergoes confor-
mational changes and inserts the amino-terminal fusion
peptide (FP) of gp41 into the host cell membrane. The
fusion mechanism involves two helical regions of gp41,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Benen et al. Journal of Biomedical Science 2014, 21:79 Page 2 of 13
http://www.jbiomedsci.com/content/21/1/79the N-terminal heptad repeat (NHR) and C-terminal
heptad repeat (CHR), which are associated to form a
pre-hairpin intermediate. In this conformation, the gp41
molecules are extended forming a trimer of CHR helices
and a trimer of NHR helices that bridge both the viral
and cellular membranes. It subsequently collapses into a
trimer-of-hairpins structure that pulls both membranes
into tight apposition and induces membrane fusion. This
structure consists of the six-helix bundle, in which three
CHR peptides pack in an antiparallel manner against a
central three-stranded coiled-coil formed by the NHR
regions [6].
Three of the identified monoclonal Abs against gp41,
denoted 2F5, 4E10 and 10E8, bind to adjacent epitopes lo-
cated in the membrane-proximal external region (MPER)
[7]. The MPER is indispensable for membrane fusion and
viral entry, and is highly conserved among HIV-1 groups.
It is accessible for IgGs already in the native envelope con-
formation, but thought to have higher accessibility during
the fusion process [8]. Some residues may be buried
within the membrane in pre-fusion and intermediate con-
formations [9]. Although 2F5 and 4E10 bind to linear core
epitopes in the MPER, a correct three-dimensional display
of their epitopes and proximal residues in the ectodomain
might enhance the recognition [10]. Additionally to bind-
ing to the gp41 protein, both 2F5 and 4E10 can interact
with membranes through hydrophobic residues in their
heavy chain CDR3 regions. A model has been suggested,
in which 4E10 first binds to the membrane, then recog-
nizes its protein epitope and locks conserved residues by
an induced-fit mechanism [9]. Removal of the membrane
component decreases binding and neutralization of these
special antibodies [11]. Taken together, these results sug-
gest displaying the MPER in a native three-dimensional
context, embedded into a membrane, for optimal mimicry
of the natural epitopes in an immunogen.
Unfortunately, the MPER is weakly immunogenic,
compared to the loop region of gp41. Past immunization
studies demonstrated that MPER-containing proteins,
fusion intermediate-mimicking proteins expressed on
HIV-1 VLPs and chimeric proteins all failed to elicit
MPER-specific neutralizing antibodies [12,13]. The anti-
body response was directed towards immunodominant,
but non-neutralizing epitopes in these studies. Others
were able to elicit high titers of MPER-targeting Abs by
a soluble 6-helix bundle immunogen, however, neutra-
lizing activity could only be detected after purification of
IgG and not in unfractionated sera [14]. Thus, the pro-
blem of eliciting high titers of anti-MPER Abs with
broadly neutralizing activity remains unsolved. A reduc-
tion of gp41 to its neutralizing epitopes, yet expanding
those sites with additional residues responsible for mem-
brane embedment and formation of the full epitopes,
seems to be a promising strategy.The objective of this work was to design and evaluate
novel immunogens based on HIV-1 gp41 MPER which
combine the above mentioned criteria. For this purpose,
variants of truncated gp41 proteins consisting of CHR,
MPER and TM regions were designed and characterized.
Heterologous peptide sequences were fused for intracel-
lular trafficking and efficient trimerization. The immu-
nogens were designed to strongly expose the MPER with
binding sites to known bnMAbs in a natural confor-
mation and membrane environment. Plasmid DNA and
pseudotyped virus-like particles (VLPs) were chosen as
immunization vehicles in a rabbit model. After a DNA
prime and VLP boost regimen, the presence of anti-
MPER Abs and neutralizing activity in unfractionated
sera was analyzed.
Methods
Software-assisted design of gp41 derivatives
An N- and C-terminally truncated gp41 (“gp41CTM”)
was designed according to Lenz et al. [15]. Wild-type
sequences for synthesis of viral gene fragments were
obtained from GenBank and optimized for human codon
usage (Life Technologies). Molecular clones of viral iso-
lates HIV-1 89.6 (subtype B, accession number U39362),
HIV-1 96ZM651 (subtype C, AF286224) and SIVmac239
(M33262) served as templates with aa 629–724 of 89.6
and 96ZM651 (HXB2 reference numbering) and aa
639–740 of SIVmac239 (SIVmac239 numbering). Mem-
brane incorporation and orientation of all constructs was
checked by the use of the transmembrane prediction
TMHMM Server v. 2.0 [16]. A human tissue plasminogen
activator (TPA) leader sequence was fused N-terminally.
Correct cleavage of the leader sequence was predicted by
SignalP 3.0 software [17]. A Kozak consensus sequence
(GCCGCCACC) was inserted 5’ of the start codon for
enhanced transcription. The sequence for an HA-tag from
Influenza virus Hemagglutinin HA1 protein (YPYDVP-
DYA) was codon-optimized and inserted C-terminally
by primer extension PCR for recognition of recombinant
proteins (primers 3E8 & 2H4/2H5/2H6, see Additional
file 1: Table S1 for primer sequences). The topology of
all gene variants was checked with Phobius Prediction
Server [18].
Trimer-stabilized constructs and molecular visualization
Two zipper domains were inserted between the TPA leader
and gp41-derived sequences by fusion PCR. One motif was
derived from the HA2 protein (amino acids 372–417,
primers 3H4 & 3H5/3H6/3H7) of human Influenza virus
strain H3 followed by a linker composed of amino acids
Gly-Ser-Thr [13]. A second domain was derived from the
GCN4 protein of Saccharomyces cerevisiae [19] (primers
3B6 & 3B7/3B8/3B9). Sequences for GCN4 and H3 zippers
were derived from Genbank (IDs: CY002064, BK006939)
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position of zippers to gp41 fragments, molecular models
were built using Modeller and evaluated by calculating the
DOPE score (Discrete Optimized Protein Energy [20].
Resulting atomic models were visualized using PyMOL
Molecular Graphics System.
SDS-PAGE, Western Blots and Slot Blots
SDS-PAGE was done with acrylamide concentrations of
12.5%. Western Blot transfers of proteins from SDS gels
were done in a semi-dry system (Serva, Heidelberg,
Germany) according to manufacturer’s instructions. For
slot blots, protein solutions were loaded onto a Bio-Dot
SF (Biorad) apparatus including 5 layers of pre-wetted
Whatman Chromatography paper (Whatman Interna-
tional Ltd, Maidstone, UK). For both methods, nitrocellu-
lose membranes with a pore size of 0.2 μm were applied
(Millipore, Bedford, USA) and blocked in TBS (150 mM
NaCl, 50 mM Tris/HCl, pH 7.4) containing 5% skim milk
powder over night at 4°C. For antibody staining, blots
were incubated for 1 h in TTBS (TBS + 0.3% (v/v) Tween-
20) with primary antibody, washed four times for 15 min
in TTBS, incubated for 1 h in TTBS with secondary anti-
body, washed again four times for 15 min in TTBS, and
subjected to either ECL (2.5 mM luminol, 0.4 mM couma-
ric acid, 0.1 M TrisHCl pH 8.5 plus equal volume of
0.018% H2O2, 0.1 M TrisHCl pH 8.5) or alkaline phos-
phatase (AP) staining solution (5 mM TrisHCl pH 9.5,
5 mM NaCl, 2.5 mM MgCl2 plus 1/50 volume of NBT/
BCIP stock (Roche)). AP reactions were stopped with
excess of dH2O. ECL reactions were measured in a
ChemiluxPro device (Intas, Göttingen, Germany). In-
tensity of bands was quantified with the aid of Gel-Pro
Analyzer software (Media Cybernetics, Bethesda, USA).
Human monoclonal antibodies (MAbs) 2F5 and 4E10
(diluted to 5 μg/ml each) served for detection of
gp41 derivatives, the HA-tag was recognized by rat
MAb 3F10 (“anti-HA High Affinity”, 0.1 μg/ml, Roche).
Pr55/p24 was detected with mouse MAb M13/5 (cell
culture supernatant, 1:500, [21]). Polyclonal HRP- or
AP-coupled anti-human-IgG, anti-rat-IgG, and anti-mouse-
IgG antibodies (all 1:2,000, all from Dako, Glostrup,
Denmark) served as secondary antibodies.
ELISA
The amount of Pr55 or p24 protein in lysates was quanti-
fied with the aid of an Enzyme-linked Immunosorbent
Assay (ELISA) using MAb M01 (1:1000, Polymun, Vienna,
Austria) as coating antibody [22]. An ELISA with gp41-
derived peptides was used to quantify anti-gp41 immuno-
globulins in animal sera by the end-point dilution method
in duplicates [23]. Peptides spanning the MPER (EQN
EKDLLALDSWNNLWNWFDITKWLWYIK) and CHR
regions (MQWDREISNYTNTIYRLLEDSQSQQEQNEK,both from Pepscan Presto BV, Lelystad, Netherlands) were
used for coating at 100 ng/ml on Nunc Maxisorp plates
(Thermo Fisher Scientific, Waltham, USA). HRP-coupled
polyclonal anti-rabbit-IgG and anti-human-IgG served as
secondary antibodies (1:4,000, Dako). Washing was done
with the aid of a high-throughput microplate washing
device (MAP-C2 workstation, Titertek Instruments Inc.,
Huntsville, USA).
Transient transfection
HEK 293 T (ATCC Microbiology Collections) were grown
in Gibco Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% fetal calf serum, 100 U/ml penicil-
lin and 0.1 mg/ml streptomycin (Invitrogen). FreeStyle
293 F cells (Invitrogen) were grown in Gibco FreeStyle
293 expression medium (Invitrogen) supplemented with
50 U/ml penicillin and 0.05 mg/ml streptomycin at
125 rpm and handled according to the manufacturer’s in-
structions. HEK293T cells were seeded in 6-well plates
(4x105 cells in 2 ml medium). 24 h after seeding, medium
was replaced by 1 ml of DMEM without supplements.
Cells were transfected with the respective expression vec-
tor(s) according to the poly-ethylenimine (PEI) transfec-
tion method using a total of 2 μg DNA and 8 μl of a
1 mg/ml PEI in H2O solution ad 50 μl DMEM without
supplements. Components were mixed, left standing for
10 min at room temperature and added drop-wise to the
cell suspension. 4 h later, transfection medium was re-
placed with 2 ml of supplemented growth medium. For
smaller (96-well) or larger (10 cm/15 cm Petri dishes) as-
says, the number of cells, the amount of DNA and PEI,
and the volume of medium was down- or up-scaled, based
on the vessel surface area. 293 F cells were adjusted to 1
million cells/ml in fresh FreeStyle medium and 30 ml of
cell suspension were transferred to 125 ml flasks. 37.5 μg
of DNA and 150 μl of PEI ad 1.8 ml DMEM without sup-
plements were mixed for transfection of one flask. 4 h
later, transfection medium was replaced with 30 ml of
FreeStyle medium supplemented with 100 U/ml penicillin
and 0.1 mg/ml streptomycin.
Cytometry
Cells were detached 48 h p.tr from wells in PBE buffer
(PBS + 1% FCS, 1 g/l NaN3, 2 mM EDTA), pelleted at
300 g for 3 min, washed in PBE, incubated with the indi-
cated fluorochrome-labeled antibodies (3 μg/ml 2F5 or
4E10, 5 μg/ml anti-HA-MAb 3F10) for 1 h at room
temperature and washed 2 times with cold PBE. 2F5
and 4E10 antibodies were labeled with AlexaFluor-647
(Protein Labeling Kit, Invitrogen) according to the man-
ufacturer’s instructions. A mean of 6 fluorochromes was
attached to each IgG molecule, as measured by photo-
metric analysis (NanoDrop software v3.7.1). anti-HA-
antibody was purchased as conjugate with Fluorescein
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7-AAD and Annexin-V-APC antibody (both diluted
1:100, both BD Biosciences). Finally, cells were subjected
to cytometric analysis in FACS Canto II (BD, with FACS
Diva software v6.0).
Sucrose gradients
After purification through a sucrose cushion, VLPs were
loaded onto a 10 ml 10-50% sucrose gradient and ultra-
centrifuged at 100,000 g for 2.5 h. 20 fractions of 0.5 ml
each were collected. For Western Blot analysis, particles
were pelleted by trichloroacetic acid precipitation. A quar-
ter of volume of 100% (w/v) TCA was added to the sam-
ples, incubated for 10 min at 4°C and spun at 14,000 g and
4°C for 5 min. The pellet was washed two times with cold
acetone, dried at 95°C for 5 min and resuspended in SDS
sample buffer. For EM experiments, fractions 13–17 were
pooled, diluted in PBS ad 12 ml, ultra-centrifuged at
100,000 g for 1.5 h and resuspended in PBS.
Electron microscopy
Sucrose-cushion purified VLPs were incubated with pri-
mary antibody 4E10 for 1 h at 37°C and further purified
on a sucrose gradient. Pooled and resuspended VLPs were
adsorbed to grids after fixation with 2% glutaraldehyde.
Grids were washed in TBS (Leica EM IGL), blocked with
3% gelatine in TBS for 1 h at RT, and incubated with an
anti-human IgG immuno-gold conjugate (particle size:
10 nm; Aurion, Wageningen, Netherlands) for 1 h at room
temperature. After three washes in TBS, grids were con-
trasted with phosphoric tungstic acid and examined in an
electron microscope (Zeiss EM 10C/CR).
VLP production
VLPs for immunization purposes were produced in 293 F
cells with the use of a codon-optimized, Rev-independent
gene for Gag(IIIB) [24]. For pseudotyped VLPs, plasmids
encoding for Gag and Env were mixed in a ratio of 2:1 in
a co-transfection assay. VLPs were harvested 72 h p.tr.,
cleared by centrifugation at 3,000 g for 15 min, loaded
onto a 30% sucrose in PBS cushion (5 ml for 30 ml of
supernatant) and ultra-centrifuged at 100,000 g for 2 h.
The pellet was resuspended overnight in PBS and stored
at −80°C, with an aliquot analyzed by SDS gel electropho-
resis and Coomassie staining for quality control. Both
VLPs and DNA for immunization purposes were checked
for low endotoxin levels with aid of Limulus Amebo-
cyte Lysate QCL-1000 assay (Lonza Group Ltd, Basel,
Switzerland), with a result of <20 EU/ml.
Rabbit immunizations
The animal study was carried out in strict accordance
with the UK Animals (Scientific Procedure) Act 1986,
and the protocol was approved by the local Ethical andWelfare Committee of the University of Cambridge and
the UK Home Office (Project license no. 80/2238). All
efforts were made to minimize suffering. New Zealand
rabbits (Harlan UK Ltd, Belton, Leicestershire, UK) were
kept under pathogen-free conditions and pre-bled by
ear vein lancing at the age of 12 weeks. Animals were
grouped into 4 groups of 6 animals each and immunized
at weeks 0 and 4 with 500 μg of plasmid DNA by i.m.
saline injection in quadriceps muscles, followed by i.m.
booster immunizations at weeks 12 and 16 with 100 μg
of VLPs (Gag protein, analyzed in Coomassie gel), adju-
vanted with 1% Carbopol 974 adjuvant. The integrity of
pseudotyped VLPs in Carbopol was checked by sucrose
gradient ultracentrifugation and following Western Blot
analysis. Rabbits were terminally bled by cardiac punc-
ture under isoflurane anesthesia and then euthanized.
Serum was obtained by incubation of blood for 1 h at
37°C, 1 h on ice, centrifugation at 20,000 g for 15 min,
and complement inactivation by incubation of super-
natant at 56°C for 30 min. Unfortunately 2 animals from
group 2 and 3 and one animal from group 1 had to be
euthanized prior to finalization of the immunization
protocol for reasons not related to the study and were
therefore not included in data analysis. Statistical ana-
lysis was performed based on the correct number of ani-
mals in each group.
Removal of anti-cell antibodies
HEK293F cells were stacked by centrifugation at 300 g
for 3 min, supernatant was aspirated and cells were
stored at 4°C for up to 5 days until usage. Stacked cells
were dissolved in an equal volume of animal serum and
shaken 3 times for 4 h at 800 rpm at room temperature,
until the signal of anti-cell antibodies was below two
times the background signal in cytometric analysis.
Neutralization assays
Virus neutralization assays were performed in the labora-
tory of D.C. Montefiori (Duke University School of Medi-
cine, Durham, USA), according to the published protocol
[25]. Assays were done with Env-pseudotyped viruses in
TZM-bl cells for isolate MW965.26 and with Env.IMC.
LucR viruses in A3R5 cells (CEM human lymphoblastoid
cell origin) for isolate SF162. Dilutions mediating inhi-
bition of infection by 50% (ID50) were subtracted by ID50
of pre-bleed sera or in any case subtracted by a minimum
of 20 (detection limit).
Statistical analysis
Significance of anti-gp41 responses in ELISA and neu-
tralizing activity in neutralization assays was determined
using the Wilcoxon Two Sample Test. Each group was
compared to its respective pre-bleeds to assess a poten-
tial neutralizing activity, and all groups were compared
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Results
Design of gp41 constructs with enhanced MPER exposure
Based on published gp41 constructs (33), novel gp41 im-
munogens were designed based on the sequence of three
molecular clones: 96ZM651 (HIV-1 clade C) was selected
for antigen development, because anti-MPER bnAbs have
been originally isolated in clade C-infected patients [26]
and clade C strains represent the majority of global HIV
infections. 89.6 (HIV-1 clade B) and SIVmac239 (“SIV”)
derived antigens served as controls. A signal peptide from
the human tissue plasminogen activator gene (TPA) was
N-terminally fused to the gp41 moiety to ensure that the
protein is efficiently directed towards the cell membrane
in mammalian cells. A hemagglutinin (HA) tag of nine
amino acids was added to the protein’s C-terminus for
uniform detection of the corresponding proteins (Figure 1).
As described earlier, the C-terminal tail partially loopsFigure 1 Design of gp41-derived immunogens. (A) Three genes based
regions (“gp41CTM”). Resulting proteins are directed by a TPA signal peptid
HA tag. Two of these are stabilized in a trimeric conformation by an N-term
representation of truncated gp41 proteins on the surface of cellular memb
C). (C) The optimal fusion site of the GCN4 zipper domain and the gp41 C
structure GCN4-NHR, and free energy was calculated with aid of DOPE sco
topology and membrane incorporation were predicted for the gp41CTM (b
derivatives (data not shown).back to the extracellular and extraviral space, enabling ac-
cess to antibodies [27]. As it is unknown whether the
CHRs adopt a trimeric or monomeric conformation in the
pre-fusion state, we designed trimer-stabilized variants in
addition to the non-stabilized structure. Trimerization is
generally thought to be beneficial for proper display of im-
munologically relevant sites within both gp41 and gp120,
which - at the same time - assists the occlusion of irrele-
vant sites believed to distract B cells from vulnerable sites.
Two heterologous trimerization domains were introduced
between the signal peptide and the gp41-derived part:
GCN4 and H3 zipper domains have been used previously
to stabilize a gp41 post-fusion [19] or intermediate struc-
ture [13,28], respectively. For the H3 zipper domain, the
orientation was adopted from an existing fusion protein
by Hinz et al. [13], including a three amino acid spacer.
Concerning the GCN4 domain, instead of fusing it to the
NHR building the inner core of 6HB [6], it was fused
N-terminally to the CHR, anticipating the stabilization of
an exposed pre-hairpin conformation [28]. The correcton gp41 were constructed in this study containing the CHR and TM
e towards the cell membrane and can be detected by a C-terminal
inal heterologous zipper motif (GCN4- or H3-derived). (B) Schematic
ranes. The amino acid sequence is derived from isolate 96ZM651 (clade
HR part was modeled by comparative modeling with the existing
re. (D) Correct cleavage of heterologous signal peptide, protein
ased on 96ZM651) protein (data shown) and zipper-stabilized
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structures of both the GCN4 domain and gp41. A mo-
lecular model of the ectodomain of a GCN4-gp41CTM
fusion protein (comprising the GCN4 zipper domain and
residues 1–50 of gp41 CHR) was built based on a solved
structure of a GCN4-NHR fusion protein (1ENV, residues
1 to 80, [19]). Another three models were built with inser-
tion of one, two, or three flexible aa (G, S, T) as linkers
using the Modeller server, and the minimized energy was
calculated by the aid of DOPE score (Figure 1C). The
model without insertions showed the minimal energy
and was chosen for cloning as it likely represents the
structure with the highest stability. Its calculated energy
(−29.7 kJ/mol) was close to that calculated for the mode-
ling template GCN4-NHR of −30.8 kJ/mol. Two further
crucial steps, the cleavage of the signal peptide and the
membrane orientation, were controlled with appropriate
prediction software. Proper signal peptide cleavage was
predicted for all constructs. However, a wrong mem-
brane orientation was predicted for the SIVmac239-based
gp41CTM construct. For this reason, the cytoplasmic tail
was elongated for 9 aa compared to 96ZM651- and 89.6-
based templates. Correct membrane topology was pre-
























































Figure 2 Membrane exposure of novel constructs and recognition by
expression plasmids containing envelope genes and stained 48 h p.tr. with Ale
antibody. (A) Comparison gp41CTM to gp145. MFI for all constructs was norm
clades B (89.6), C (96ZM651) and SIVmac239 by extracellular staining with ant
to gp41 variants, normalized to the fluorescence intensity of their simultaneo
independent experiments.exemplarily for basal construct gp41CTM based on isolate
96ZM651).
Membrane exposure and selective recognition by
bnMAbs
Expression and membrane location of gp41 variants is a
prerequisite for incorporation into VLPs, display of rele-
vant epitopes and usability in immunization studies. In a
first experiment, in vivo properties of gp41CTM were
evaluated in comparison to gp145, which is a codon-
optimized version of gp160 with mutated cleavage site
and truncated C-terminal tail which increases surface
presentation [29]. The clade C molecular clone 96ZM651
was intended to serve as source for cloning the Env/gp41
derivatives. The clade B isolate 89.6 and SIVmac239 were
chosen as additional controls for proper display, as they
possessed either both or none of the epitopes for 2F5 and
4E10, respectively. HEK293T cells were transfected with
expression plasmids encoding gp145 and gp41CTM and
stained with the mentioned bnMAbs. gp41CTM exhibited
a slightly, yet non-significantly, enhanced mean fluores-
cence intensity (MFI) in cytometric analysis compared to
gp145 (Figure 2A). The staining with 2F5 and 4E10























































bnMAbs. 293 T cells were transfected with equal masses of pcDNA3.1(+)
xaFluor647-labelled 2F5 or 4E10 bnMAbs and Fluorescein-labeled anti-HA
alized to those of gp41CTM(89.6). (B) Detection of gp41 derivatives of
i-HA antibody, normalized to gp41CTM(89.6). (C, D) 2F5 and 4E10 binding
us anti-HA staining. Error bars indicate the standard deviation of three
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96ZM651-based constructs. Following staining of the
HA-tag with an anti-HA-antibody, all variants showed
proper membrane localization and similar expression
levels (Figure 2B). For linking bnMAb binding with the
level of Env expression, MFIs of 2F5 and 4E10 were nor-
malized to the anti-HA intensity. The SIVmac239-based
variants bound to none of the tested bnMAbs and were
only detectable by the HA-tag, as expected. Signal in-
tensities were similar for the basal and trimer-stabilized
constructs, which indicated a similar accessibility of
bnMAb epitopes in these constructs, irrespective of tri-
merization domains.
Incorporation of oligomeric gp41 derivatives into VLPs
Further analysis of gp41 variants was restricted to the
constructs based on the molecular clone 96ZM651, as
these were chosen for following immunization studies.
As it is known that HIV-1-derived VLPs band at a den-
sity of 1.14-1.18 g/cm3 corresponding to ~35% glucose
in PBS [30], the incorporation of novel gp41 immuno-
gens into VLPs was addressed by sucrose gradients and
Western Blot analysis. VLPs were produced by co-
transfection of HEK293T cells with plasmids encoding
Gag and gp41CTM by RNA- and codon-optimized
genes, respectively. Gag as well as gp41 derivatives that
were incorporated into VLPs prior to or during budding
were detected in Western Blot analysis using poly-
peptide specific antibodies. All variants showed a co-
banding of both proteins in fractions 12–14, suggesting
successful incorporation into VLPs (Figure 3A). Higher
molecular weight bands for GCN4-gp41CTM and H3-
gp41CTM indicated the formation of stable dimers and
trimers. For a relative quantification of incorporated
gp41 proteins, VLPs were purified, normalized to Gag
content, lysed and loaded onto a slot blot, followed by
detection with 4E10 (Figure 3B). All gp41 variants ex-
hibited similar signal intensities and are therefore sup-
posed to be incorporated at similar amounts into VLPs.
Since the recognition by 4E10 of a similar soluble stand-
ard protein (GCN4-gp41CTM-FD) was substantially
lower than that of gp41CTM and its derivatives (data
not shown), it was not possible to determine the abso-
lute number of gp41CTM molecules on the surface of
VLPs. The morphology of VLPs pseudotyped with gp41
derivatives and the antigenic properties of incorporated
proteins were further evaluated by electron microscopy.
VLPs were labeled with 4E10 and secondary immuno-
gold antibody. gp41 derivatives had no apparent impact
on particle morphology and size of 100–150 nm in
diameter (Figure 3C). Staining with 4E10 showed spe-
cific labeling of VLPs pseudotyped with all three types
of gp41 derivatives, whereas non-pseudotyped VLPs
were not labeled.Induction of anti-gp41 antibodies
The immunogens were evaluated for immunogenicity in
a rabbit immunization study. A DNA prime and VLP
boost regimen was chosen, because heterologous im-
munization schedules using other Env constructs had in-
duced higher antibody titers compared to DNA or VLPs
alone [31]. After attesting low endotoxin levels in the
immunogens formulation, VLPs were formulated with
1% 974 carbopol as adjuvant. Carbopol was chosen be-
cause of its optimal formulation properties with lipid
membranes, compared to Freund’s adjuvant or oil in
water formulations. The integrity of VLPs and incorpo-
rated proteins after mixing with Carbopol was verified
by sucrose gradient and Western Blot analysis (data not
shown). Rabbits were first primed twice with 500 μg of
DNA at weeks 0 and 4, then boosted two times with
100 μg of VLPs formulated in Carbopol, at weeks 12 and
16 (Figure 4A). Bleeds were taken 2 weeks before the
first immunization and 2 weeks after the last immu-
nization. The induction of anti-gp41 Abs is a prerequi-
site for effective neutralization, and was analyzed by IgG
ELISA. Reactivity of sera was dissected using an MPER
(Figure 4C) and a CHR peptide immobilized to the solid
phase (Figure 4D). Whereas animals that received gp145
(positive control) developed significant titers against
both peptides, only low titers were obtained for the
groups that were immunized with gp41 derivatives. Im-
mune responses in non-reacting animals might have
been too low to be detected in unfractionated sera.
Neutralizing capacity of unfractionated immune sera
Immunization of rabbits with VLPs derived from hete-
rologous production systems (HEK293T cells) can induce
antibodies directed against HEK293T cell derived mem-
brane proteins, and these antibodies interfere with neu-
tralization assays. As anti-cell antibodies were detected in
some immunized animals (Figure 5A), sera were incu-
bated with HEK293T cells three times to absorb and de-
plete anti-cell antibodies [32]. Antibodies directed against
a 30-mer MPER-peptide, that were present in animal sera,
were not detectably affected by this procedure (Figure 5B,
upper panel), while anti-cell antibodies were successfully
removed (Figure 5A). As a control, 2F5 and 4E10 recom-
binant antibodies were incubated with HEK293 cells as
well, and were depleted partially in this assay. 4E10 was
depleted more pronouncedly than 2F5, as 4E10 has a
higher membrane-binding activity than 2F5 (Figure 5B,
lower panel). Subsequently, all sera were tested in stan-
dardized assays for neutralizing activity in a TZM-bl assay.
A tier-1 molecular clone of clade C (MW965.26) and a
tier-1 clone of clade B (SF162) were chosen for readout.
Clade C isolate MW965.26 contains the 4E10 epitope but
not the 2F5 epitope, like 96ZM651, whereas clade B iso-
late SF162 contains the epitopes for both 4E10 and 2F5,
Figure 3 Biochemical characterization of VLPs containing gp41 variants. (A) Incorporation of gp41 derivatives into VLPs. VLPs were produced
as described above and analyzed in 10 to 50% sucrose gradients. 20 fractions were collected and loaded on a reducing SDS gel, respectively. gp41
variants were detected by anti-HA antibody and Pr55Gag by anti-p24 MAb 13/5 in subsequent Western Blot analysis. Co-banding of Gag (only shown
for basal construct gp41CTM) and gp41 variants in fractions 11–15 indicates incorporation into virus-like particles. Higher molecular weight bands for
GCN4- and H3-gp41CTM indicate stable dimeric and trimeric conformations. VLPs produced by transfection of Gag without gp41 were negative for
anti-HA-antibody staining (data not shown). (B) Quantification of gp41 derivatives in VLPs. 0.25 μg of indicated lysed pseudotyped VLPs were loaded
onto a slot blot, and stained with 4E10 and anti-human-HRP antibody. (C) Functional preservation of bnMAb epitopes on VLPs. VLP morphology and
epitope preservation were verified by immuno-gold labeling and electron microscopy. VLPs were purified and incubated with human bnMAb 4E10
and gold-labelled anti-human antibody. VLPs pseudotyped with gp41CTM, GCN4-gp41CTM and H3-gp41CTM showed specific staining with 4E10. VLPs
without pseudotyping exhibited no labeling (right).
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http://www.jbiomedsci.com/content/21/1/79like isolate 89.6 [33]. In general, results from neutra-
lization tests tended to reflect titers of anti-MPER-peptide
antibodies as measured in ELISA. Effective neutralization
was observed only for the rabbit group receiving gp145
DNA and homologous VLPs (VLP-gp145), with two rab-
bits showing neutralization at a 50% inhibitory dilution
(ID50) of >1,000 against MW965.26 (Figure 6A). For all
three rabbit groups receiving gp41-derived DNA primeand VLP boost, neutralizing activities were weak. How-
ever, statistically significant neutralization at low level was
observed for group 1 against MW965.26 and group 2
against SF162. An ID50 of up to ~100 could be detected
in several further animals against both isolates. Interes-
tingly, neutralizing activity of sera of group 1–3 after gp41
immunization appeared to be more pronounced against
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Figure 4 Anti-gp41 antibodies induced by immunization. (A) Immunization protocol. Rabbits were immunized twice with DNA encoding for
trimer-stabilized constructs and twice with homologous VLPs at indicated time points. (B) Three groups receiving gp41CTM and trimer-stabilized
constructs were assigned. One group receiving gp145 DNA and VLPs served as control group. (C,D) Terminal bleeds of rabbits were analyzed by
IgG ELISA. Peptides spanning the MPER (C) and CHR (D) served as coating peptides. Anti-rabbit-HRP coupled antibody was used as secondary
antibody. Titers are calculated as reciprocal dilutions of specific signals which are at least two-fold above pre-bleed signals. Asterisks above single
groups mark a mean titer significantly above background level (p < 0.05).
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tained with group 4 after gp145 immunization.
Discussion and conclusions
Previous attempts to elicit nAbs against the 2F5 [34,35]
and the 4E10 epitope [36,37] have largely failed, empha-
sizing the challenges associated with generating a focused
response to MPER-neutralizing epitopes. However, an ap-
proach that combines the exposure of neutralizing sites
on the immunogen fixed in a favorable structure following
truncation of unwanted or immunodominant epitopes
and presented in a membrane environment may be ef-
fective. Therefore, this work focused on the creation and
immunological evaluation of novel gp41-derived immuno-
gens, which meet the above mentioned requirements of
such an MPER-based immunogen.
Various steps were undertaken to improve exposure of
conserved regions, to stabilize relevant conformations
and to focus B cell responses: (i) gp41 was truncated
N-terminally to eliminate dispensable sites; (ii) the CHR
was included to promote proper trimerization and
MPER folding and (iii) the gp41 C-terminus was trun-
cated to allow for efficient incorporation into VLPs [29]and to support an optimal configuration for 4E10 epi-
tope exposure [38].
Cytometric analyses validated membrane topology and
binding to bnMAbs 2F5 and 4E10. Signals for 2F5 and
4E10 epitopes as well as the C-terminally fused HA tag
were low, but significant and specific, indicating a low
level of presentation, yet proper membrane incorporation.
The recognition of the HA-tag located in the antigenic re-
gion of the “Kennedy sequence” in the cytoplasmic tail
supports the hypothesis of additional membrane-spanning
domains leading to exposure of the tag [39-42]. Electron
microscopy experiments of VLPs stained with 4E10 clearly
demonstrated the gp41 derivatives to be presented on the
surface of VLPs. Higher molecular weight bands of
trimer-stabilized envelopes (Figure 3) upon assessment of
VLPs by Western Blot analysis indicated a high stability of
dimeric and trimeric assemblies. According to previous
finding by Lenz et al. [15], the observed shift towards di-
and trimeric conformations following N-terminal fusion
of the zipper domains (gp41CTM) may be a result of
GCN induced trimer formation, trimer stability or both.
Generally, trimeric conformations are considered supe-
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Figure 5 Removal of anti-cell antibodies. (A) Effective removal of anti-cell antibodies in sera of immunized animals. Sera of rabbits were incubated
with human 293 cells for 4 h at room temperature with moderate shaking. Three rounds of incubation were sufficient to remove all significant anti-cell
activity, measured by staining of human 293 T cells with dilutions of sera and PE-labeled anti-rabbit antibody. Mean fluorescence intensity (MFI) of a
representative serum is shown. (B) Anti-MPER antibodies 2F5 and 4E10, but not anti-gp41 Abs induced by immunization were depleted by incubation
with cells. Serial dilutions of 2F5, 4E10 and immune sera in PBS were incubated three times with an equal volume of HEK293F cells. Supernatants were
read out in a gp41 ELISA with MPER peptide as coating reagent, and anti-human-HRP coupled antibody as secondary antibody.
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immunodominant epitopes disclosed by the monomeric
protein [43]. Taken together, the in silico models of de-
signed gp41 variants could be implemented into pro-
teins with the desired biochemical specifications.
For immunogenicity studies a DNA prime and VLP
boost regimen of rabbits was chosen as a positive effect
of DNA priming on antibody titers had been observed
by others studying immunogenicity of MPER-containing
proteins [31]. Inter-individual variations in gp41 specificIgG responses within groups were notable, which had
also been observed before [43]. gp41 specific antibody
titers induced by any gp41 DNA prime/VLP boost com-
bination were generally weak compared to titers deter-
mined in the gp145 control group. As reactivities against
MPER and CHR were similarly low in groups receiving
gp41CTM and trimer-stabilized derivatives, the low re-
activity may be attributed to low protein expression and
exposition on the VLP surface. This limitation may be
overcome by using heterologous transmembrane domains
MW965.26





















Figure 6 Induction of low neutralizing antibody titers in rabbit sera after immunization with gp41 derivatives. After removal of anti-cell
antibodies, sera were tested in neutralization assays with two viral strains. Dilutions mediating inhibition of 50% infection (ID50) subtracted by
ID50 of pre-bleed sera are shown. Sera of all groups were tested against tier-1 isolates (A) MW965.26 (clade C) and (B) SF162 (clade B). Asterisks
mark significant difference between groups (p < 0.05).
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previously shown to mediate enhanced incorporation and
display of truncated Env proteins [29]. Moderate neutra-
lization found in animals immunized with VLPs present-
ing gp145 on their surface may benefit from (i) increased
numbers of presented Envelopes and (ii) from the ad-
ditional epitopes such as e.g. V3 and others presented by
the gp120 moiety of gp145.
Sera were pre-incubated several times with non-
transduced HEK293T production cells to remove anti-
cell antibodies from immune sera prior to neutralization
assays. Figure 5a demonstrates as exemplified by sera
obtained from rabbit 10 that the pre-incubation proced-
ure leads to a significant reduction of anti-cell antibodies
below the level detected in the corresponding prebleed
serum. Whereas Figure 5b (lower panel) demonstrates
for 2 MPER specific MAbs, 2F5 and 4E10, that the pre-
incubation procedure reduces the binding of these
MAbs to a 30-mer MPER-peptide, the upper panel
depicting the reactivity of selected antisera before and
after the pre-incubation procedure does not provide any
evidence for removal of MPER-specific antibodies.
However, despite these ELISA binding data we cannot
completely rule out the possibility that there was a sub-
species of 2F5- or 4E10-like antibodies, which was not
captured by the 30-mer linear MPER-peptide but may
have been depleted by pre-incubation procedure. As a
consequence, future immunization studies engrafting the
MPER on VLPs should emphasize the production of
VLPs in cell-lines derived from the homologous species
to be immunized.
Neutralization in our study was observed only in sera
which proved to contain ELISA reactive antibodies. How-
ever, whereas a previous study claimed that trimer
stabilization of VLP-exposed MPER peptides exhibit a
beneficial effect on the formation of neutralizing antibody
titers [31], our constructs induced comparable neutra-
lizing titers irrespective of the absence or presence of thefused trimerization domain (Figure 4). As the gp41CTM
core construct used in this study comprised a more ex-
tended CHR portion (55 residues) compared to the more
truncated forms (42 and 24 residues) used by others [31],
the longer CHR per se may already be sufficient to sup-
port or stabilize gp41CTM trimerization and proper dis-
play in vivo.
Recent studies underscored the importance of the mem-
brane environment to properly present MPER immuno-
gens to B cells. Consistently it was demonstrated that
these approaches can induce a low titer of neutralizing
antibodies, yet highlight the difficulty of achieving high ti-
ters [44,45]. Some other immunogen designs where the
MPER had been fused to various heterologous carriers
elicited strong peptide specific reactivities, yet had not
been successful in showing HIV-1 neutralizing activity
[46,47] The gp41 constructs presented here were antigenic
for 4E10 and induced a basic level of neutralization, which
needs to be further enhanced - a common phenomenon
among recent gp41 immunization studies [48-52]. Finally,
a study by Bomsel et al. showed that not only neu-
tralization, but also transcytosis-blocking properties and
antibody-dependent cellular-cytotoxicity may protect from
SHIV infection after animals had been immunized with
virosomes containing an MPER peptide [53]. Thus, assess-
ment of IgG neutralizing activity of sera in vitro may not
reflect protection at mucosal sites in situ. The evaluation
of functional parameters other than neutralization, such
as ADCC, ADVI and transcytosis blocking, may be of
value in future MPER targeting studies.
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